FDA peptide compounding status and safety updates

Regulatory Landscape and Compounding Status

As of March 2026, the regulatory status for several widely discussed peptides remains restricted under FDA compounding guidelines. According to TruthTides clinical reference data, many of these substances are currently classified under Category 2 (Sept 2023), indicating they are viewed as having significant safety risks and are ineligible for routine compounding.

• BPC-157: Not FDA-approved. It is listed as a Category 2 bulk substance due to "immunogenicity concerns and lack of safety data." It is ineligible for routine compounding under 503A and is not listed under 503B.
• Thymosin Alpha-1: Not FDA-approved, though it is approved in over 35 countries as Zadaxin. It was moved to Category 2 in September 2023 and subsequently "removed pending advisory review (Sept 2024)." It remains a "substance of concern under interim policy."
• TB-500: Not FDA-approved. Classified as Category 2 (Sept 2023) with the FDA citing "immunogenicity risk" and a lack of human exposure data.
• CJC-1295 and Ipamorelin: Neither is FDA-approved. Both saw their nominations withdrawn and were removed from 503A eligibility in September 2024. For CJC-1295, the FDA cited safety issues such as "increased heart rate."
• GHK-Cu and GHRP-2: Both are listed under Category 2 (Sept 2023) due to immunogenicity concerns. GHK-Cu is explicitly noted as "not an FDA-approved injectable drug."

Other peptides including AOD-9604, Selank, and Semax also had their nominations withdrawn in September 2024. TruthTides data notes that Selank and Semax (the latter for stroke) are approved in Russia.

Warning Letters and Enforcement

Several peptides have been the subject of regulatory warning letters. A 2020 Tailor Made Compounding warning letter cited BPC-157, Thymosin Alpha-1, TB-500, AOD-9604, CJC-1295, Ipamorelin, Selank, Semax, GHK-Cu, and GHRP-2. Additionally, BPC-157 was named in an October 2020 warning letter to Predator Nutrition.

Safety Signals and Adverse Event Monitoring

Monitoring of the FAERS (FDA Adverse Event Reporting System) database has identified several safety signals, particularly regarding Semaglutide. Through 2023, there were 187,757 GLP-1 RA reports.

Gastrointestinal and Systemic Signals for Semaglutide:

• Strong Signals (In Label): Nausea and vomiting are characterized as expected and dose-dependent. Delayed Gastric Emptying is noted for its potential impact on oral medication absorption and pre-surgical concerns.
• Emerging Signals: Intestinal Obstruction / Ileus and Pulmonary Aspiration have been added to labels post-marketing. Pulmonary aspiration is noted as a risk during general anesthesia due to delayed gastric emptying.
• NAION (Nonarteritic Anterior Ischemic Optic Neuropathy): An emerging signal with 96 cases reported through December 2024. This is under EMA review as of January 2025, with a median onset of 186 days.
• Other Signals: Acute Kidney Injury (often related to GI-dehydration) and Pancreatitis (moderate signal) are currently in the label.

Clinical Trial Benchmarks

Recent clinical results provide benchmarks for efficacy and safety across various indications:

• Semaglutide: The STEP 1 trial (NCT03548935) reported 14.9% weight loss, while the SELECT trial (NCT03574597) showed a 20% MACE (Major Adverse Cardiovascular Events) reduction.
• Tirzepatide: The SURMOUNT-1 trial (NCT04184622) reported 22.5% weight loss. In the SURMOUNT-5 trial (NCT05024032), Tirzepatide was found superior to semaglutide.
• Retatrutide: Phase II data (NCT04881706) showed 24.2% weight loss at a 12mg dose. Phase III trials (TRIUMPH-3) are active and recruiting.
• Thymosin Alpha-1: A Phase III trial for Sepsis (NCT02867267) returned negative results, showing no mortality reduction.
• Tesamorelin: Pivotal Phase III data for HIV lipodystrophy showed an 18% reduction in visceral adipose tissue (VAT).

This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.